Month: September 2020

AMSTERDAM, Sept. 22, 2020 (GLOBE NEWSWIRE) — TomTom (TOM2), the leading independent location technology specialist, today announced that it will provide Maserati with maps, navigation software and connected services for the all-new Maserati Intelligent Assistant (MIA) in-vehicle infotainment system. Drivers of upcoming Ghibli, Levante and Quattroporte models will be the first to benefit from a wide range of innovative features provided by TomTom, including: IQ Maps, traffic, connected navigation services, destination prediction, and a premium user interface. The Ghibli, Levante and Quattroporte will hit the road in October, whilst other models like the recently unveiled MC20 supercar will follow in 2021.“We are delighted that our premium navigation will now power Maserati’s exclusive sports cars,” said Antoine Saucier, Managing...

Gene expression data may explain differences in clinical adverse event profiles of FGFR inhibitorsAntitumor activity of derazantinib in preclinical cancer models with FGFR aberrations supports planned gastric cancer studyFull results from the completed phase 1 study in patients with brain cancer underscores the potential for lisavanbulin to be developed in a targeted patient population using end-binding protein 1 (EB1) as a patient selection criterionBasel, Switzerland, September 22, 2020Basilea Pharmaceutica Ltd. (SIX: BSLN) today reports on several e-posters with new preclinical and clinical data on its fibroblast growth factor receptor (FGFR) inhibitor derazantinib and its tumor checkpoint controller, lisavanbulin, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which took place from 19-21 September,...

Genexpressionsdaten könnten Unterschiede in Nebenwirkungsprofilen von FGFR-Inhibitoren erklärenAntitumor-Aktivität von Derazantinib in präklinischen Tumormodellen mit Aberrationen der FGFR-Gene unterstützt geplante Studie in MagenkrebsVollständige Ergebnisse aus der abgeschlossenen Phase-1-Studie bei Patienten mit Hirntumoren unterstreichen das Potenzial einer gezielten klinischen Entwicklung von Lisavanbulin für bestimmte Patientenpopulationen, unter Verwendung von End–binding protein 1 (EB1) als AuswahlkriteriumBasel, 22. September 2020Basilea Pharmaceutica AG (SIX: BSLN) informierte heute über eine Reihe von E-Postern mit neuen präklinischen und klinischen Daten zu ihrem FGFR-Inhibitor Derazantinib und ihrem Tumor-Checkpoint-Controller Lisavanbulin, die auf der Jahrestagung 2020 der Europäischen Gesellschaft für medizinische...

 Pressemeddelelse                                                                           22. september 2020 Styrk bundlinjen – nu kan det betale sig for SMV’er at automatisere manuelle pluk af emner i kasser. Scape Technologies’ løsninger er ikke forbeholdt store industrivirksomheder. Scape lancerer nu en ny brugervenlig bin-picker, der gør det nemt at øge produktiviteten og samtidig forbedre medarbejdernes fysiske arbejdsmiljø til en pris, der også gør det rentabelt for små virksomheder og virksomheder uden automatiseringserfaring. Nyskabelsen SCAPE Easy-Picker frigør mandetimer brugt på manuelle pluk af emner i kasser; tid som i stedet kan bruges på mere komplekse og værdiskabende opgaver.Tilslut og pluk. Scape Technologies sætter igen nye standarder for såkaldte Pick & Place og Bin-Picking løsninger med en ny brugervenlig...

AttachmentPDF

Pièce jointePDF

Pratteln, Switzerland, September 22, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. and their academic collaborators have published new open-label, long-term clinical data on the safety, tolerability and efficacy of vamorolone in patients with Duchenne muscular dystrophy (DMD). These 18-month treatment data extend previously published 24-week treatment data, and show a reduction of corticosteroid-specific side effects and sustained efficacy with vamorolone including clinical improvement through the 18-month follow-up period.This publication in the journal PLOS Medicine [1] provides peer-reviewed and detailed open-label data in patients with DMD treated for 18 months with vamorolone. A multi-center, open-label, 24-week trial (VBP15-003; [2, 3]) with a total 24-month long-term extension (VBP15-LTE;...

Pratteln, Schweiz, 22. September 2020 – Santhera Pharmaceuticals (SIX: SANN) gibt die Veröffentlichung von neuen offenen, klinischen Langzeitdaten zur Verträglichkeit und Wirksamkeit von Vamorolone bei Patienten mit Duchenne-Muskeldystrophie (DMD) durch ReveraGen Biopharma Inc. und dessen akademischen Partnern bekannt. Diese 18-Monats-Behandlungsdaten erweitern zuvor veröffentlichte 24-Wochen-Behandlungsdaten und zeigen mit Vamorolone eine Verringerung der unter einer Kortikosteroid-Standardtherapie am häufigsten auftretenden Nebenwirkungen und eine nachhaltige Wirksamkeit einschliesslich einer klinischen Verbesserung während der 18-monatigen Beobachtungszeit.Diese Publikation im Journal PLOS Medicine [1] enthält von Fachkollegen begutachtete und detaillierte Open-Label-Daten bei Patienten mit DMD, die 18 Monate lang mit Vamorolone behandelt...

Press releaseParis, 22 September 2020Transactions carried out as part of a share buyback program and outside of a liquidity contractOrange announces that it has purchased treasury shares within the framework of its 2020 share buyback program.These shares have been acquired to honour obligations related to long term incentive plans corporate officers and senior employees. The long term incentive plans, which are conditional on presence and performance, were set up with the aim of involving Group key managers in the success of the “Essentials2020” and “Engage2025” strategic plans.Name of the issuer: Orange (LEI: 969500MCOONR8990S771)References of the share buyback program: A description of the program authorised by the Shareholders’ General Meeting held on 19 May 2020 (16th resolution) can be found in Orange’s 2019 universal...